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Abstract 
Thermally triggered drug release from temperature-sensitive liposomes (TSL) holds great promise for cancer 
therapy. Different types of TSL have been designed recently for heat triggered drug release inside tumor 
blood vessels or after accumulation into the tumor interstitium. However, justification of drug release profiles 
was mainly based on in vitro release data. While these methods could be good enough to give early 
indication about the thermal sensitivity of TSL, they are still far from being optimum. This is because these 
methods do not take into consideration the actual adsorption of proteins onto the surface of TSL after their in 
vivo administration, also known as ‘protein corona’ and the influence this could have on drug release. 
Therefore, in this study we compared thermal triggered drug release profile of two different types of 
doxorubicin encapsulated TSL; namely the lysolipid-containing TSL (LTSL) and traditional TSL (TTSL) after 
their in vivo recovery from the blood circulation of CD-1 mice. Ex vivo release profile at 42°C was then tested 
either in the presence of full plasma or after removal of unbound plasma proteins (i.e. protein corona coated 
TSL). Our data showed that the influence of the environment on drug release profile was very much 
dependent on the type of TSL. LTSL release profile was consistently characterized by ultrafast drug release 
independent on the conditions tested. On the contrary, TTSL release profile changed significantly. 
Doxorubicin release from in vivo recovered TTSL was slow and incomplete in the presence of unbound 
plasma proteins, whereas very rapid drug release was detected from in vivo recovered and purified protein 
corona-coated TTSL in the absence of unbound proteins. Using mass spectrometry and quantification of 
protein adsorption, we confirmed that this discrepancy is due to the changes in protein adsorption onto TTSL 
when heated in the presence of unbound proteins leading to reduction in drug release. In summary this study 
showed that the formation of the in vivo corona on TSL will have a dramatic impact on their release profile 
and is dependent on both their lipid composition and the protein content of the environment in which drug 
release is triggered.  
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Highlights 
In this study we investigated in detail the effect of in vivo protein adsorption onto the surface of TSL, also 
known as ‘protein corona’ on drug release profile from TSL. Our data illustrated that the formation of the in 
vivo corona on TSL liposomes has a dramatic impact on their release profile. This effect is dependent on 
both TSL lipid composition and the protein content of the environment in which drug release is triggered. Our 
findings emphasize that the design of TSL for thermal triggered release cannot be predicted based on 
chemical composition and in vitro release studies only, but the environment of drug release should be 
considered.  
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Introduction 
Thermosensitive liposomes (TSL) represent a very promising ‘smart generation’ of 
liposomal systems for targeted and triggered drug release in response to external mild 
hyperthermia. Following the pioneering work of Yatvin in the late 1970s,[1] a lot of effort has been 
invested to explore the potential of TSL for cancer therapy. Indeed, over the past thirty years the 
development of TSL has been widely expanded starting from the molecular design of TSL all the 
way to clinical testing and determining their therapeutic aptitude [2]. Encapsulation of drug inside 
TSL, shields the body from the harmful effects of the drug when circulating in the blood stream. 
Once within the tumor, drug release from TSL can be tailored towards intravascular [3-7] or 
interstitial release [4, 8] based on the timing between TSL administration and heat application. 
Generally, drug release from TSL is based on passive permeability through the lipid membrane 
when it passes through transition temperature (Tm). At body temperature the lipid membrane exists 
in solid phase only and therefore no release of hydrophilic drugs is expected. When TSL heated 
through their Tm, areas of the phospholipid molecules start to change from the solid (ordered) gel 
phase to the liquid (disordered) crystalline phase. This creates boundaries with packing defects 
between the two phases through which the drug permeability is enhanced. [2, 9] In addition to that, 
lysolipids containing TSL mediate ultrafast drug release through the formation of lysolipids 
stabilized long lasting pores [10]. The release of encapsulated molecules is also affected by the 
loading mechanism. Significant difference in the release rate of fluorescent dyes, such 
carboxyfluorescein (CF), was observed compared to doxorubicin (DOX) when tested under the 
same conditions. This difference is due to the collapse of the pH gradient mechanism used for 
DOX loading when the proton ions diffusion across the lipid membrane increases at Tm [11, 12].  
For a long time, the release profile from early types of TSL was misinterpreted as slow and 
incomplete under mild HT. Similarly, the relatively high Tm of this type of TSL (42-45ºC) suggested 
that high thermal dose, 1h heating at temperature > 42ºC, is essential to achieve complete drug 
release. However, those assumptions were based on in vitro release data generated mainly in 
buffers and do not reflect the complexity of the physiological conditions [13-15]. It has been 
repeatedly reported that nanoparticles are spontaneously coated by proteins, once in contact with 
biofluids. Proteins adsorbed onto the surface of nanoparticles form a complex bioshell, known also 
as ‘protein corona’, the composition of which is highly affected by the physicochemical 
characteristics of nanoparticles. [16-19] Protein corona formation has been previously investigated 
for different types of liposomes, however little is known about protein corona formation on TSL. [20-
24]  While the effect of protein corona on the cellular internalization [25], cytotoxicity [26, 27] and 
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targeting capability [28-30] have been so far explored in depth, the impact of protein corona on the 
release profile of active molecules from nanoparticles has not been systematically studies.[31] 
Most of the previous studies, as will be explained in more details in the discussion, utilized in vitro 
drug release profile in the presence of plasma proteins to get early indication about the 
thermosensitive nature of TSL and the rate of drug release. However, these would not reflect the 
effect of actual protein adsorption under in vivo conditions.  
In our previous studies, we developed a robust protocol, to investigate the in vivo protein 
corona formed onto clinically-used liposomes and more recently onto gold nanoparticles[32] after 
their recovery from the blood circulation of mice. These studies demonstrated that the molecular 
complexity and morphology of the in vivo protein corona cannot be adequately predicted by the in 
vitro plasma incubation of NPs.[23, 24] Even though the overall protein adsorption was found to be 
reduced by the functionalization of liposomes with PEG, it could not be fully suppressed.[23, 24] 
Unlike previous work, in the present study, we investigated the role of protein corona on thermal 
triggered release of TSL after their in vivo recovery. In this way we can better simulate the actual 
Figure 1: Schematic description of the experimental design including;(A) Composition of different temperature 
sensitive liposomes (TSL) used in the study, namely lysolipids TSL (LTSL) and traditional TSL (TTSL);(B) In vivo 
protein corona formation after intravenous injection (i.v.) into tail vein (n = 3 CD-1 mice/group; 3 independent 
experiments replicated). Ten minutes after injection TSL were recovered from the blood by cardiac puncture and 
the plasma was then separated from the recovered blood by centrifugation; (C) Protein-coated TSL were purified 
from unbound proteins with and without ex-vivo heating at 42 °C for 1h; (D) Protein-coated TSL were characterized 
in terms of morphology, thermal sensitivity and protein adsorption profile. 
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protein adsorption profile compared to simple in vitro incubation (Figure 1). In vivo protein coronas 
formed onto two different types of intravenously administered and doxorubicin-encapsulated TSL, 
namely traditional TSL (TTSL) and lysolipid-containing TSL (LTSL), were quantitatively and 
qualitatively characterized by mass spectrometry based proteomics. We hypothesized that TSL 
thermosensitivity is not only affected by the protein corona composition, but also by the 
environment in which the drug release is triggered. Therefore, we tested ex-vivo the release profile 
of doxorubicin from in vivo recovered corona-coated TSL (at 42°C), in the presence of full plasma 
(in the presence of unbound proteins) and in buffer (i.e. protein corona coated TSL in the absence 
of unbound proteins). 
 
Results 
Physicochemical Characterization of TSL before and after in vivo recovery 
The physicochemical characteristics of TTSL and LTSL liposome systems employed in this study 
are summarized in Figure 2 and Supporting table 1. Dynamic light scattering (DLS), ζ-potential 
measurements and negative stain transmission electron microscopy (TEM) were performed prior to 
the in vivo administration to analyse the properties and morphology of TSL in the absence of 
protein adsorption. TTSL and LTSL liposome systems had a mean hydrodynamic diameter 
between 120-130 nm and a negative surface charge of 25–30 mV. All liposomal formulations 
displayed low polydispersity values (<0.07) indicating a narrow size distribution. TEM imaging 
showed well-dispersed, round shaped vesicles and their size correlating that of DLS 
measurements (Figure 2C).  
To investigate in vivo protein corona formation, TTSL and LTSL were intravenously injected and 
recovered from the blood circulation of CD-1 mice by cardiac puncture (Figure 1). We have 
previously shown that a complex protein corona is formed as early as 10 minutes post-injection.[24] 
Our previous time evolution data demonstrated that despite the highly dynamic protein binding 
kinetics, protein corona formed onto PEGylated liposomal doxorubicin does not quantitatively 
change overtime.[23] In addition to that, our previous pharmacokinetics studies with TTSL and 
LTSL showed that approximately 60-70% of the injected TSL is still in the circulation 10 minutes 
post-injection which allows maximum liposomes recovery.[6] For the above reasons in this study 
we chose to investigate in vivo protein corona formation 10 min post-injection. A protocol 
combining size exclusion chromatography and membrane ultrafiltration was used for the isolation 
of corona-coated TSL from unbound and loosely bound plasma proteins, as we have previously 
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described [23, 24]. To characterize protein coronas formed in vivo (at 37°C), liposomes were 
immediately purified from unbound proteins after intravenous administration, while to investigate 
the effect of mild HT on the formation of protein corona, in vivo recovered plasma (containing TSL 
liposomes) was incubated at 42 °C for 1h, prior to the purification of corona-coated liposomes 
(Figure 1C).  
The physicochemical properties of the in vivo recovered protein-coated TSL with and 
without prior heating at 42°C are shown in Figure 2. Dynamic light scattering measurements of 
corona-coated TSL demonstrated that their size distribution broadened (larger polydispersity 
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Figure 2: The effect of protein corona formation on the physicochemical characteristics of TSL. Mean diameter 
(nm) and ζ-potential (mV) distributions are depicted for (A) TTSL and (B) LTSL liposome systems, before and 
after their interaction with CD-1 mouse plasma at 37°C and 42°C. The graphs are representative samples from 
three independent experiments. (C) Negative stain transmission electron microscopy images showing the 
morphological and structural characterization of LTSL and TTSL systems before and after protein corona 
formation at 37 °C and 42 °C. All scale bars are 100 nm. 
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index), while their surface charge remained negative, both at 37°C and 42°C. In agreement with 
our previous studies investigating liposomal protein corona formation, we observed a blood-
induced reduction in the mean diameter of liposomes, attributed to their high elastic structure [23, 
24]. This ‘shrinkage effect’ was much more pronounced when corona-coated liposomes were 
exposed to mild hyperthermia (Table S1). In terms of structural integrity and morphology, TEM 
images revealed well-dispersed liposomes that retained their structural integrity after in vivo 
recovery, while the adsorption of proteins onto their surfaces was clearly evident. Ex-vivo heating 
(at 42°C) of the in vivo recovered TTSL did not seem to affect their shape, whereas morphological 
changes towards elongated vesicles were observed in the case of LTSL. The structural differences 
observed between TTSL and LTSL after hyperthermia could be explained by their different lipid 
composition and especially their unique thermal responsive components [33, 34]. LTSL are 
considered to be less robust compared to TTSL as no cholesterol is included in their design, in 
addition to the inclusion of 10mol% of lysolipids that leads to pores formation after heating at 42°C 
[34, 35]. 
Having studied TSL surface properties and morphology, TSL systems stability and thermal 
responsiveness were initially evaluated in vitro by studying the release of doxorubicin (DOX) from 
the liposomes at 37°C and 42°C, respectively. In agreement with our previous findings,[6] TTSL 
liposomal system showed very good drug retention capability after their in vitro incubation in full 
plasma at 37°C (<10% DOX leakage in 24h). LTSL system on the other hand, exhibited short drug 
retention window of < 2h (Figure S1A). Thermal triggered drug release from TSL (at 42°C) was 
first evaluated using traditional in vitro release methods in in buffer (Figure 3A) and full plasma 
(Figure 3B). As expected from the chemical design of these two liposomal systems, LTSL showed 
very fast and complete drug release compared to slower release profile from TTSL after incubation 
with plasma proteins (Figure 3B). While, similar thermal drug release profile was observed when 
the in vitro release was performed in buffer in the case of LTSL, very limited DOX release was 
observed (< 10%) for TTSL system (Figure A). The presence of plasma proteins clearly favoured 
the temperature sensitivity of TTSL, presumably by gaining access into the grain boundary of the 
lipid membrane at the transition temperature (Tm); (Figure 3B).  
Because of the significant role plasma proteins play on thermal properties of some types of 
TSL and the fundamental differences in protein corona formation between in vitro and in vivo 
conditions, we studied thermal sensitivity of TSL after in vivo recovery from the blood circulation of 
CD1 mice. The percentage of DOX release at 42°C was measured ex vivo in the presence and 
absence of unbound proteins (Figure 3 C&D). Interestingly, as can be observed in Figure 3C, 
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purified corona-coated TTSL (in buffer), showed very fast and complete DOX release at 42°C. 
TTSL thermal release in that case was almost identical to LTSL system. In contrast, ex vivo release 
at 42°C from TTSL, in plasma, exhibited significantly slower drug release (p<0.05). LTSL thermal 
triggered release on the other hand was still characterized by fast drug release even when heated 
in the presence of unbound proteins (Figure 3D). 
 
In order to understand the differences in the release profiles observed under the different 
conditions tested, we quantitatively and qualitatively characterized the in vivo protein corona 
formed onto the two different types of TSL. The amount of protein adsorbed was quantified by 
calculating the protein binding ability (Pb), defined as the amount of proteins associated with each 
μmol of lipid. Interestingly, we observed that the in vivo recovered LTSL adsorbed higher amount of 
protein than TTSL (Figure 4A). In fact, compared to our previous studies [23, 24], LTSL adsorb 
almost three times more proteins than Doxil-like non-temperature sensitive PEGylated liposome 
system [23, 24]. This observation can be due to the difference in the fluidity of the phospholipid 
bilayers that can greatly influence the total amount of protein adsorbed.  
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Figure 3: Temperature sensitivity of TTSL and LTSL liposome systems after 1h heating in a water bath at 
42°C. The percentage of doxorubicin release from TTSL and LTSL was measured; (A) after in vitro 
incubation in HBS buffer pH 7.4, (B) after in vitro incubation with full CD-1 mouse plasma, (C) from the in 
vivo recovered and purified liposomes (in the absence of unbound proteins) and (D) from the in vivo 
recovered liposomes in full plasma (before purification of unbound proteins). Statistical analysis of DOX 
release from TTSL from in vivo recovery in the presence and absence of unbound proteins using two-tailed 
unpaired student t-test revealed significant differences (p values < 0.05) at all time points tested. 
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In addition, protein adsorption profile after heating at 42°C revealed a pronounced increase 
in the total amount of protein adsorbed for both, TTSL and LTSL (Figure 4A). The increased 
amount of adsorbed proteins in the case of TTSL heated ex-vivo at 42°C in the presence of free 
plasma proteins is most likely due to the increase in the bilayer fluidity. This change from the gel-
phase into the liquid crystalline phase could facilitate the incorporation of more proteins into the 
phospholipid bilayers. These data explain the highly variable release profile observed from TTSL in 
the different conditions tested. TTSL liposomes released <10% of encapsulated DOX when heated 
in buffer (Figure 3A). This is expected from the chemical composition of TTSL. The rigid nature of 
TTSL due to the presence of cholesterol and HSPC lipids increases Tm to 44°C. Therefore, when 
heated at 42°C very minimum release detected, hence most of the lipid molecules are in a highly 
ordered state when not in interaction with plasma proteins. In comparison, complete and ultrafast 
Figure 4: Comparison of protein adsorption profiles onto TTSL and LTSL formed at 37°C and 42°C. (A) 
Comparison of the amount of proteins adsorbed onto TTSL and LTSL liposome systems. Pb values (μg of 
protein/μM lipid) represent the average and standard error from three independent experiments, each using 
three mice per liposome system; (Bi) Venn diagrams report the number of unique proteins identified in the 37°C 
and 42°C formed coronas on the two liposomal formulations tested and their respective overlap; (Bii) Venn 
diagrams illustrate the effect of temperature protein corona formation for TTSL and LTSL; (C) Classification of 
the corona proteins identified according to their molecular mass. 
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release was observed from in vivo recovered protein-coated TTSL heated in buffer shown in 
Figure 3C, which indicates that the interaction of plasma proteins with the lipid membrane is critical 
to facilitate drug release from the lipid bilayer during heating. It is important to stress here that the 
conditions tested in this case (Figure 3C) are artificial lab conditions and may not directly reflect 
what can happen in vivo. On the other hand, heating TTSL in full plasma both in vitro and after in 
vivo recovery showed slow and incomplete release profile (Figure 3B&D) which indicates that the 
increased adsorption of free protein in solution on TTSL surface during heating at 42°C can act as 
a barrier to release. The release profile after heating in full plasma in vitro (Figure 3B) was slightly 
faster than that detected from in vivo recovery (Figure 3D). The differences in structural 
configuration and composition of in vitro and in vivo formed protein coronas, as we reported before 
[24], might explain such variability in the release profile.  
The amount of adsorbed proteins on LTSL was also found to increase after heating at 42°C 
in full plasma. Despite this increase, DOX release profile from LTSL did not significantly change in 
the presence and absence of unbound proteins (Figure 3C&D). Complete drug release was 
observed from LTSL under both heating conditions tested, however, a slightly slower release was 
seen in the first 5 minutes when heated in the presence of unbound proteins. Based on these 
results, it seems that LTSL thermal release mechanism which depends on the long lasting pores 
formation by the lysolipids components is possibly still retained after 10 minutes circulation in vivo. 
This effect has been investigated in details by Banno et al [36], showing that the retention of  
lysolipids in LTSL is compromised. A rapid loss of lysolipid molecules from LTSL was observed 
within the first 10 minutes (from 9.6% to 3.6%) and this loss continued over time. However, the 
study showed that the thermosensitvity of LTSL was still retained despite such loss. In agreement 
with our release data, Banno et al observed >80% DOX release from LTSL recovered 10 minutes 
post-injection despite the rapid loss of lysolipid molecules. Therefore, this makes LTSL liposome 
system ideal for intravascular drug release (if heated shortly after injection), where heating occurs 
in excess of free plasma protein, compared to TTSL liposome system.  
Proteins associated with TTSL and LTSL liposome systems at 37°C and 42°C were 
separated by SDS-PAGE and visualized with EZ Blue staining (Figure S2). In agreement with 
protein quantification results, LTSL were found to adsorb the highest amount of proteins which 
further increased at 42°C. 
A comprehensive identification of proteins associated with TSL at 37°C and 42°C was 
performed by mass spectrometry. The Venn diagrams in Figure 4Bi illustrate the number of 
common and unique proteins adsorbed onto TTSL and LTSL at 37°C and 42°C. The majority of 
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proteins identified were common between TTSL and LTSL both at 37°C (n= 343) and at 42°C (n= 
436). However, the unique proteins identified (at both 37 and 42°C) demonstrated that the 
difference in liposomal composition between TTSL and LTSL shapes protein corona formation, as 
previously shown by others [37]. Due to the tendency of lysolipid loss from LTSL, different protein 
adsorption profile may change overtime and would certainly worth more investigation. The 
temperature was also found to greatly influence protein adsorption profiles (Figure 4Bii). 
Mahmoudi et al. have previously investigated the effect of temperature on protein corona formation. 
The in vitro incubation of superparamagnetic nanoparticles with protein solutions at different 
temperatures, ranging from 5 ºC to 45 ºC resulted in different degree of protein coverage and 
different corona composition.[38] In our study, hyperthermia was not only found to increase the 
total amount of protein adsorbed onto the surface of liposomes but also modified the composition 
of protein corona. The ex vivo heating of TTSL and LTSL at 42°C was found to increase the 
complexity of protein corona, especially in the case of LTSL, where 321 unique proteins were 
identified. Our results also demonstrate that hyperthermia results in the replacement of some 
proteins (initially interacted with liposomes at 37 °C) by others. This is well illustrated by the 173 
and 142 proteins, found on the surface of TTSL and LTSL respectively, only at 37 °C.  
We have also classified the protein adsorption profile on TTSL and LTSL liposome systems 
based on the molecular weight of the proteins adsorbed. As illustrated in Figure 4C, the majority of 
the bound proteins (>85%) are of low molecular weight (MW<80). This was in strong agreement 
with previous observations by us and others [23, 26], that the protein adsorption tendency under 
dynamic conditions is towards low molecular weight. Very little fluctuation in the contribution of 
each protein group (classified based on MW) on the corona composition was observed between 
the two liposomes tested at 37°C and 42°C. This indicates that the formation of long lasting pores 
after LTSL heating at 42°C [34] did not further enhance low molecular weight protein adsorption.  
To better understand the protein corona formation onto TSL, we determined the relative protein 
abundance (RPA) of identified proteins. Figure 5 summarizes the 20 most abundant proteins 
adsorbed onto in vivo recovered TTSL and LTSL before and after ex vivo heating. Apolipoproteins 
and immunoglobulins were the most abundant classes of corona proteins present in both 
conditions. RPA values demonstrated that for the two types of TSL tested the ranking of the most 
abundant proteins changed after ex vivo heating. For example, the RPA of Apolipoprotein C-III has 
dramatically decreased on both TTSL and LTSL after heating. Interestingly, albumin that is usually 
used as model protein to simulate the effect of protein adsorption on the release profile [39] was 
not identified in the top 20 proteins, both at 37°C and 42°C. This indicates the specificity of the 
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interaction of TSL with plasma proteins, as our previous findings demonstrated that serum albumin 
is indeed in the top 20 proteins adsorbed onto in vivo recovered Doxil-like non-temperature 
sensitive PEGylated liposome system [23, 24]. This also implies that the most abundant proteins in 
the plasma are not necessarily the most abundant corona proteins.[23, 24] 
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Discussion 
 
Thermal triggered drug release from TSL, represents a very promising and rapidly evolving 
area in particular for cancer therapy [2]. Among the different triggering modality, mild hyperthermia, 
has provided to be one of the most promising and well controlled triggering modalities and has 
Figure 5: Most-abundant proteins (top-20) identified adsorbed onto TTSL and LTSL systems after protein 
corona formation at (A) 37°C and (B) 42°C measured by LCMS/MS. Relative protein abundance (RPA) values 
represent the average and standard error from three independent experiments, each using 3-4 mice. 
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already progressed towards clinical evaluation [40-42]. The success of this smart delivery approach 
depends on achieving the desirable balance between minimising drug leakage at body temperature 
and maximizing drug release in the heated tumour [8]. Based on that, in vitro testing of drug 
release rate at body temperature and mild hyperthermia range (41-43°C), has always been 
considered a prerequisite for early prediction of the therapeutic effectiveness of TSL [5, 6, 43-45]. 
However, the weakness of these traditional techniques is that the performance of TSL in vitro 
cannot directly predict their behaviour under the complex in vivo conditions. Koning and co-workers 
have depicted recently the different factors that can influence the performance of TSL with the aim 
to get more understanding about the extent that in vitro testing can be translated into in vivo 
therapeutic effect. These factors include; the TSL blood kinetics, the timing between injection and 
HT, duration of HT and the tumour vascularisation [46].  
One of the most important and instant factor is the change in surface properties of TSL 
once in the blood stream as a result of plasma protein adsorption. It is now well accepted that TSL 
behaviour is highly influenced by blood components in particular plasma proteins to variable 
degrees depending on the lipid composition. [2, 6, 14, 33, 39]. PEGylation could increase blood 
circulation time and improve thermal properties of TSL, but was shown not to be able to prevent the 
interaction with plasma proteins [33, 39]. Hossann et al has recently attempted to identify the effect 
of individual plasma components that essentially affect the integrity and thermal sensitivity of TSL. 
In that particular study, the rate of drug release from different types of TSL was tested in the 
presence of albumin, immunoglobulin and lipoprotein since they represent the major protein 
components in human blood. The conclusion of that study was that individual serum proteins 
cannot predict the complex composition of full plasma, therefore, the use of plasma or serum were 
considered inevitable for evaluation of TSL stability and thermal sensitivity [39]. However, the effect 
of serum on the release profile can vary considerably with the origin of the serum used, its 
concentration and the duration of exposure. This can explain the discrepancy in the release data 
reported from different TSL systems [14, 47]. The effect of plasma components on the thermal 
sensitivity of TSL can also justify the increase in therapeutic activity observed in a number of 
preclinical studies over a wide range of tumor models despite being considered of having slow and 
incomplete drug release using mild heating conditions (42°C) in vitro [48]. This effect has been 
studied in details recently by Lokerse et al, where they compared four different types of TSL 
composed of DPPC:DSPC:DSPE-PEG2000 but with different proportions of DPPC:DSPC lipids. In 
vitro release data after 1h heating at 42°C revealed that drug release rate decrease with increasing 
DSPC lipid mol% and indeed cryo-TEM images of liposomes at DPPC:DSPC 50:50mol% 
confirmed that most of those liposomes were filled with DOX crystals which verify the slow and 
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incomplete release profile. Those differences in release profile were less apparent in vivo, using 
intravital microscopy. Moreover, a burst effect was observed which was unexpected based on in 
vitro testing which again confirm the limitation of in vitro testing to predict therapeutic effectiveness 
[46]. 
Similar findings were reported before by Li et al using real-time imaging. Efficient 
intravascular DOX release after heating at 42ºC was observed followed by rapid uptake of DOX by 
endothelial cells and tumor cells. This resulted in high and homogeneous DOX penetration into 
tumor cells and improved tumor growth control [11]. Li observations are in a good agreement with 
Manzoor et al observations showing rapid intravascular release from LTSL followed by 
extravasation into tumour tissue [3]. 
Similarly, biomolecular adsorption can influence the drug retention and in vivo behaviour of 
other types of nanocarriers. Peng et al has illustrated that pre-exposure of polymeric nanocarriers 
(loaded with coumarin-6) to bovine serum albumin reduce the drug release rate and has significant 
impact on in vivo behaviour (prolonged blood circulation time and changed organs distribution 
profile) [49]. Protein corona can also reduce burst release effect observed with protein conjugated 
nanocarrier (e.g. Abraxane) and surface-loaded nanocarrier (e.g. iron oxide nanoparticles) [50]. 
The observed decrease in drug release in those studies became more evident in the presence of 
unbound proteins, presumably because this will be associated with additional shielding effect [50]. 
Although those studies concerned with drug release at body temperature, it agrees with our 
findings that heat triggered drug release from TTSL was slow and incomplete when tested in the 
presence of unbound plasma proteins.  
In addition to the effect of protein corona on drug release properties, recent efforts have 
illustrated that protein corona layering around nanoparticles can act as a reservoir with high 
payload capacity for therapeutic molecules such as anticancer drugs or genetic materials [51, 52]. 
The release of protein corona loaded drugs can be controlled in different ways utilising the 
properties of the core NP. An interesting example on that is using thermal triggered release of DOX 
incorporated into protein corona layer around gold nanorods (GNR). Upon exposure to external 
laser, incorporated DOX was released, possibility due to the restructuring process of protein corona 
as a result of protein denaturation in the proximity of GNR [52].  
Our findings illustrated that the interaction of plasma proteins with TSL is changed after 
heating and this change is affected by many parameters such as the lipid composition of TSL and 
temperature. The variability of the protein adsorption has a clear influence on the real 
thermosensitivity and drug release profile observed. This observation was supported for the first 
time with morphological data that illustrated a very clear change in protein corona layer on TSL 
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when heated in the presence of unbound proteins. Furthermore, we provided a comprehensive 
analysis of protein corona composition using mass spectroscopy. This illustrated that testing drug 
release by simple in vitro incubation is of limited value to predict the complex liposomal-protein 
interactions in vivo and the influences those can have on thermal triggered release. Over the past 
few years, several TSL systems have been designed to trigger drug release either intravenously, 
while still in the blood stream, or after accumulation into the tumour interstitium. As the protein 
species will differ significantly between the blood and tumour, the change in the release 
environment should be carefully considered. 
To put this into a clinical context, our findings will have a great impact on the critical 
evaluation of TSL and iterate on the necessity to take into account the different parameters that 
can affect drug release. In phase III clinical trial of ThermoDOX® in combination with 
radiofrequency ablation (RFA) for hepatocellular carcinoma, initial data showed that the treatment 
did not meet the expected therapeutic efficacy compared to RFA control group. However, a recent 
meta-analysis of the data revealed 58% improved overall survival in a subgroup of patients who 
received optimized RFA for at least 45 min. It is highly believed now that the timing and duration of 
heating may be the critical factors behinds ThermoDOX® clinical trial data, in addition to other 
peripheral hurdles that were experienced in some clinical centres [53, 54].  
Taking all the above into consideration, it is evident that further systematic preclinical and 
clinical studies are required to offer insight into the best combination of TSL and HT protocol 
applied taken into consideration the chemical design of TSL and the complexity of the in vivo 
environment where the actual heat-triggered release will take place.  
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Conclusion 
Our findings illustrated that the interaction of plasma proteins with TSL is a highly variable 
process and affected by many parameters. The variability of the protein adsorption has a clear 
influence on the real thermosensitivity and drug release profile observed. This effect was very 
much dependent on the lipid composition of the liposomes tested and was not predictable. Using 
mass spectrometry and quantification of protein adsorption, we confirmed that the discrepancy in 
heat-triggered profile is due to the changes in protein adsorption. This illustrated that testing drug 
release by simple in vitro incubation is of limited value to predict the complex liposomal-protein 
interactions in vivo and the influences this can have on thermal triggered release. In summary, this 
study showed that designing TSL for thermal triggered release cannot be predicted based on 
chemical composition and in vitro release studies only, but the environment of drug release should 
be taken into account.  
 
  
19 
 
Experimental 
 
Materials 
Dipalmitoylphosphatidylcholine (DPPC); monostearoyl phosphatidylcholine (MSPC); hydrogenated soy 
phosphatidylcholine (HSPC); 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-2000] (ammonium salt) (DSPE-PEG2000) were purchased from Lipoid GmbH (Germany). 
Cholesterol, chloroform, methanol, 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), and 
doxorubicin hydrochloride (Dox) were purchased from Sigma (UK). All chemical substances and solvents 
were used without further purification. 
 
Liposome preparation and DOX encapsulation 
Two different types of TSL (TTSL and) were prepared by a thin lipid film hydration method followed by 
extrusion as described previously. Table S1 shows the liposomal formulation employed, the lipid composition 
and the molar ratios. Briefly, lipids were dissolved in chloroform:methanol mixture (4:1) in a round bottom 
flask and the organic solvents were then evaporated using a rotary evaporator to produce dried lipid films. 
Lipid films were then hydrated with ammonium sulphate 250 mM (pH 8.5) at 60 °C and small unilamellar 
liposomes were produced by extrusion through 800 nm and 200 nm extrusion filters (Whatman, VWR, UK) 5 
times each then 10 times through 100 nm filters (Whatman, VWR, UK) using a mini-Extruder (Avanti Polar 
Lipids, Alabaster, AL). Liposome size and surface charge were measured by using Zetasizer Nano ZS 
(Malvern, UK). 
Doxorubicin (DOX), an anticancer drug, was loaded into TSL by the ammonium sulphate gradient method. 
First, external buffer was exchanged by passing the liposomes through Sepharose CL-4B gel filtration 
column equilibrated with HBS buffer, then incubated with DOX at 1:20 DOX/Lipid mass ratio at 37 °C for 
LTSL (1.5 h) or at 39 °C for TTSL (5 h). After incubation, liposomes were passed through PD-10 desalting 
columns (GE Healthcare Life Sciences) to remove any free DOX. Encapsulation efficiency (% EE) was 
calculated by comparing the total fluorescence intensity of DOX post and pre gel filtration. 
 
% EE= I(t) post column / I(t) pre column *100 
 
Where, I(t) is the total fluorescence intensity of the liposome suspension after adding 2 µL Triton X-100 (10% 
in HBS, pH 7.4). 
 
Animal experiments  
Eight to ten week old female CD1 mice were purchased from Charles River (UK).Animal procedures were 
performed in compliance with the UK Home Office Code of Practice for the Housing and Care of Animals 
used in Scientific Procedures. Mice were housed in groups of five with free access to water and kept at 
temperature of 19-22 °C and relative humidity of 45-65%. Before performing the procedures, animals where 
acclimatized to the environment for at least 7 days. 
 
TSL recovery after in vivo administration 
CD1 mice were anesthetized by inhalation of isoﬂurane and TSL were administered intravenously via the 
lateral tail vein, at a lipid dose of 0.125mM/g body weight to achieve a final doxorubicin dose of 5mg/kg body 
weight, used for preclinical studies. [5, 7, 35] 10 minutes post- injection, blood was recovered by cardiac 
puncture using K2EDTA coated blood collection tubes. Approximately 0.5-1ml of blood was recovered from 
each mouse. Plasma was prepared by inverting 10 times the collection tubes to ensure mixing of blood with 
EDTA and subsequent centrifugation for 12 minutes at 1300 RCF at 4 °C. Supernatant was collected into 
Protein LoBind Eppendorf Tubes and the plasma samples obtained from three mice were pooled together for 
a final plasma volume of 1 ml. Three experimental replicates were performed and therefore 9 mice were used 
in total for each time point.  
 
Serum stability and temperature sensitivity of liposomes 
In vitro release experiments were performed at 37°C and 42°C in full CD-1 mouse serum prepared by 
collecting 0.5-1ml of blood by cardiac puncture from each mouse using K2EDTA coated blood collection 
tubes. Blood samples were inverted 10 times to ensure proper mixing of blood with EDTA followed by 
subsequent centrifugation for 12 minutes at 1300 RCF at 4 °C. Release studies experiments performed with 
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TSL recovered after in vivo administration were done either directly after recovery (in full plasma in the 
presence of free unbound plasma proteins) or after separation of protein-coated liposomes from unbound 
and weakly bound proteins  
 
At different time points 10μL samples were withdrawn and further diluted to 200μL with HBS (pH 7.4) and 
measured at 480nm excitation wavelength and 593nm emission wavelength (slit 10/20nm) in a quartz 
cuvette using Cary Eclipse Fluorescence Spectrophotometer (Agilent Technologies). The intensity of the 
fluorescence signals was then normalized and the % of Dox release was calculated as; Dox release 
%=[I(s)−I(0)]/[I(t)−I(0)], where I(s) is the fluorescence intensity of individual samples at different time points, 
I(0)is the background fluorescence intensity of liposome samples after purification and I(t)is the fluorescence 
intensity of liposomes suspension after lysis with 3μL of 1% Triton X-100 in HBS followed by heating at 42°C 
for 20 minutes. 
 
Separation of protein-coated liposomes from unbound and weakly bound proteins  
TTSL and LTSL liposome systems recovered from in vivo experiments were separated form excess plasma 
proteins by size exclusion chromatography followed by membrane ultrafiltration, as we have previously 
described.[24] This process has been done wither immediately after the in vivo incubations (Protein-coated 
liposomes at 37°C) or after 1h ex-vivo heating at 42°C (Protein-coated liposomes at 42°C). In both cases 1ml 
of plasma samples containing in vivo recovered liposomes with and without heating at 42°C was loaded onto 
a Sepharose CL-4B (SIGMA-ALDRICH) column (15x1.5cm) equilibrated with HBS. Chromatographic 
fractions 4,5 and 6 containing liposomes were then pooled together and concentrated to 500μl by 
centrifugation using Vivaspin 6 column (10000 MWCO, Sartorious, Fisher Scientific) at 3000 rpm. Vivaspin 
500 centrifugal concentrator (1 000 000 MWCO, Sartorious, Fisher Scientific) was then used at 3000 rpm, to 
further concentrate the samples to 100μl and to ensure separation of protein-coated liposomes from the 
remaining large unbound proteins. Liposomes were then washed 3 times with 100μl HBS to remove weekly 
bound proteins.  
 
Please note that the procedures of liposomes purification with Sepharose CL-4B and Vivaspin has no impact 
on liposomes size and DPI. These are routinely used procedures for DOX encapsulation (table S1).  
 
Size and zeta potential measurements using dynamic light scattering (DLS) 
After incubation of liposomes at different temperature for each condition tested, DLS measurements were 
performed at RT (25°C). Liposome size and surface charge were measured using Zetasizer Nano ZS 
(Malvern, Instruments, UK). For size measurement, samples were diluted with distilled water in 1ml cuvettes. 
Zeta potential was measured in disposable Zetasizer cuvettes and sample dilution was performed with 
distilled water. Size and zeta potential data were taken in three and five measurements, respectively. 
 
Transmission electron microscopy (TEM)  
TSL under different conditions tested were visualized with transmission electron microscopy (FEI Tecnai 12 
BioTwin) before and after their in vivo interaction with plasma proteins at 37°C and 42°C. Samples were 
diluted to 1mM lipid concentration, then a drop from each liposome suspension was placed onto a Carbon 
Film Mesh Copper Grid (CF400-Cu, Electron Microscopy Science) and the excess suspension was removed 
with a filter paper. Staining was performed using aqueous uranyl acetate solution 1%. 
 
 
Quantification of adsorbed proteins  
Proteins associated with recovered liposomes were quantified by BCA Protein assay kit. Pb values, 
expressed as μg of protein/µM lipid were then calculated and represented as the average ± standard error of 
three independent experiments. For the BCA assay, a 6-point standard curve was generated by serial 
dilutions of BSA in HBS, with the top standard at a concentration of 2μg/ml. BCA reagent A and B were 
mixed at a ratio of 50:1 and 200μl of the BCA mixture were dispensed into a 96-well plate, in duplicates. 
Then, 25μl of each standard or unknown sample were added per well. The plate was incubated for 30 
minutes at 37°C, after which the absorbance was read at 574nm on a plate reader (Fluostar Omega). Protein 
concentrations were calculated according to the standard curve. To quantify lipid concentration, 20μl of each 
samples was mixed with 1ml of chloroform and 500 μl of Stewart assay reagent in an Eppendorf tube. The 
samples were vortexed for 20 seconds followed by 1 min of centrifugation at 13 000 rpm. 200μl of the 
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chloroform phase was transferred to a quartz cuvette. The optical density was measured using Cary 50 Bio 
Spectrophotometer (Agilent Technologies) at 485nm. Lipid concentration was calculated according to a 
standard curve.  
 
Mass Spectrometry 
Proteins associated with 0.05μM of in vivo recovered TSL were mixed with Protein Solving Buffer (Fisher 
Scientific) for a final volume of 25μl and boiled for 5 minutes at 90°C. Samples were then loaded in 10% 
Precise Tris-HEPES Protein Gel (Thermo Scientific). The gel was run for 3-5 minutes 100V, in 50 times 
diluted Tris-HEPES SDS Buffer (Thermo Scientific). Staining was performed with EZ Blue™ Gel Staining 
reagent (Sigma Life Science) overnight followed by washing in distilled water for 2h. Bands of interest were 
excised from the gel and dehydrated using acetonitrile followed by vacuum centrifugation. Dried gel pieces 
were reduced with 10mM dithiothreitol and alkylated with 55mM iodoacetamide. Gel pieces were then 
washed alternately with 25 mM ammonium bicarbonate followed by acetonitrile. This was repeated, and the 
gel pieces dried by vacuum centrifugation. Samples were digested with trypsin overnight at 37°C. 
 
Digested samples were analysed by LC-MS/MS using an UltiMate® 3000 Rapid Separation LC (RSLC, 
Dionex Corporation, Sunnyvale, CA) coupled to Orbitrap Velos Pro (Thermo Fisher Scientific) mass 
spectrometer. Peptide mixtures were separated using a gradient from 92% A (0.1% FA in water) and 8% B 
(0.1% FA in acetonitrile) to 33% B, in 44min at 300nL min-1, using a 250mm x 75μm i.d. 1.7μM BEH C18, 
analytical column (Waters). Peptides were selected for fragmentation automatically by data dependant 
analysis. Data produced were searched using Mascot (Matrix Science UK), against the [Uniprot] database 
with taxonomy of [mouse] selected. Data were validated using Scaffold (Proteome Software, Portland, OR). 
 
The Scaffold software (version 4.3.2, Proteome Software Inc.) was used to validate MS/MS based peptide 
and protein identifications and for relative quantification based on spectral counting. Peptide identifications 
were accepted if they could be established at greater than 95.0% probability by the Peptide Prophet 
algorithm with Scaffold delta-mass correction. Protein identifications were accepted if they could be 
established at greater than 99.0% probability and contained at least 2 identified peptides. Protein 
probabilities were assigned by the Protein Prophet algorithm.  Proteins that contained similar peptides and 
could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of 
parsimony. Semi quantitative assessment of the protein amounts was conducted using normalized spectral 
counting, NSCs, provided by Scaffold Software. The mean value of NSCs obtained in the three experimental 
replicates for each protein was normalized to the protein MW and expressed as a relative quantity by 
applying the following equation: 
  
 
 
where, MWNSCk is the percentage molecular weight normalized NSC for protein k and MW is the molecular 
weight in kDa for protein k. This equation takes into consideration the protein size and evaluates the 
contribution of each protein reflecting its relative protein abundance (RPA). 
 
Statistical Analysis  
Statistical analysis of the data was performed using Graph Pad Prism software. Two-tailed unpaired student 
t-test was used and p values < 0.05 was considered significant.  
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Supporting TableS1: Physicochemical Characterization of LTSL and TTSL used in this study: 
Hydrodynamic Diameter, Polydispersity Index, Zeta-Potential 
 
TSL system / 
 lipid molar ratios 
Hydrodynamic 
diameter(nm) 
Polydispersity 
Index, PDI 
Zeta Potential, 
ζ (mV) 
TTSL 
DPPC:HSPC:CHOL:DSPE-
PEG2000 (54:27:16:3)  
Liposomes without 
DOX 127.9 ± 1.6 0.05 ± 0.021  
Liposomes DOX 
before injected  132 ± 1.8 0.07 ± 0.009 -29.7 ± 1.01 
Protein-coated 
liposomes at 37°C 112 ± 03 0.17 ± 0.010 -33.3 ± 2.40 
Protein-coated 
liposomes at 42°C 102 ± 04 0.16 ± 0.010 -34.1 ± 1.50 
LTSL 
DPPC:MSPC:DSPE-
PEG2000 (90:10:4) 
Liposomes without 
DOX 124.5 ± 1.77 0.075 ± 0.014  
Liposomes DOX 
before injected  122 ± 1.2 0.06 ± 0.005 -24.6 ± 0.67 
Protein-coated 
liposomes at 37 108 ± 03 0.15 ± 0.010 -35.6 ± 2.30 
Protein-coated 
liposomes at 42°C 95.9 ± 2.98 0.19 ± 0.020 -36.1 ± 2.01 
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Supporting Figure S1: Serum stability and temperature sensitivity of TTSL and LTSL liposome systems 
before injection. The percentage of doxorubicin release from TTSL and LTSL liposomes was measured 
before injection in full CD-1 mouse plasma at 37°C over 24h. 
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 Supporting Figure S2: EZ-Blue stained SDS-PAGE gel comparing the protein adsorption profiles onto 
TTSL and LTSL formed at 37°C and 42°C. SDS-PAGE data showed qualitatively higher protein adsorption 
onto LTSL liposome system at 42°C compared to LTSL liposomes at 37°C and TTSL liposomes at both 
conditions tested. 
